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==========================

Dysferlinopathy is a group of autosomal recessive muscular dystrophies caused by mutations in dysferlin(*DYSF*) gene showing marked clinical heterogeneity.\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6]\] The most common phenotypes of dysferlinopathy are proximal limb weakness (limb girdle muscular dystrophy type 2B \[LGMD2B\])\[[@ref1]\] and distal myopathy (Miyoshi myopathy \[MM\]).\[[@ref2]\] However, other atypical symptoms such as hyperCKemia,\[[@ref7]\] distal anterior compartment myopathy,\[[@ref8]\] and proximodistal myopathy (PDM)\[[@ref3]\] are not rare and can have a congenital onset.\[[@ref9]\] Clinical variability is also observed within a single family.

Western blot analysis and immunohistochemistry are important tools in the initial diagnosis of primary dysferlinopathy due to their low cost and convenience in clinical practice.\[[@ref10]\] However, severe reduction of *DYSF* can also be observed in other skeletal muscle diseases, such as calpainopathy, caveolinopathy, and anoctaminopathy, which are classified as secondary dysferlinopathies.\[[@ref11]\] In addition, false-negative results can occur in western blot analysis when *DYSF* has accumulated in the cytoplasm.\[[@ref12]\] Therefore, gene analysis is necessary and still remains the "gold standard" for diagnosis.\[[@ref13]\]

The *DYSF* gene is located on chromosome 2p13, which spans a genomic region of more than 230 kbp and comprises 55 exons.\[[@ref1][@ref2]\] It encodes a transmembrane protein *DYSF* which has been linked to membrane repair,\[[@ref14]\] Ca^2+^ signaling,\[[@ref15]\] cell adhesion,\[[@ref16]\] and angiogenesis.\[[@ref17]\] To date, 510 different mutations in this gene have been reported in the Leiden muscular dystrophy database worldwide (Leiden Muscular Dystrophy pages © [www.dmd.nl](www.dmd.nl)). Most of these mutations are private and there are no hotspots,\[[@ref18]\] which makes screening of the entire coding sequence of the *DYSF* gene necessary. In addition, most of the reported mutations are point mutations, small deletion/insertions, and intronic mutations.\[[@ref18]\] Exonic rearrangements had been reported on rare occasions and were identified as the second disease-causing mutation in 5 of 12 patients by multiplex ligation-dependent probe amplification (MLPA).\[[@ref19]\] Given the high frequency of patients with only one pathogenic mutation (the proportion varied from 12.5% to 34.0% in previous studies),\[[@ref4][@ref5][@ref18]\] it is necessary to carry out MLPA testing in these patients as a supplementary tool in the routine screening for *DYSF* gene mutations.

To date, no more than 60 Chinese dysferlinopathy patients with genetic diagnoses had been reported.\[[@ref4][@ref20][@ref21][@ref22][@ref23]\] To better characterize the genetic spectrum of Chinese patients with dysferlinopathy, we described the genetic and clinical findings in the largest cohort of Chinese dysferlinopathy patients. In addition, we performed MLPA assay of *DYSF* gene in patients with only one pathogenic mutation to confirm the existence of exonic rearrangements in Chinese patients.

M[ethods]{.smallcaps} {#sec1-2}
=====================

Patient selection criteria and clinical evaluation {#sec2-1}
--------------------------------------------------

Eighty-seven patients were included in this study based on the clinical suspicion of primary dysferlinopathy and absent/severely reduced dysferlin expression as evidenced by immunohistochemical analyses of muscle specimen. Written informed consent was obtained from all participants according to the *Declaration of Helsinki*. All these patients underwent muscle biopsy at Department of Neurology, Peking University First Hospital after providing written informed consent. Immunohistochemical analyses were performed using primary antibodies for DYSF, sarcoglycans, and dystrophin (all from Novocastra Laboratories, Newcastle, UK). Two patients were included with a clinical suspicion of dysferlinopathy without a muscle biopsy. All patients underwent detailed neurological interviews and physical examinations by experienced neurologists (Zhao-Xia Wang, Wei Zhang, or Yun Yuan) at Department of Neurology, Peking University First Hospital. Patients were classified into different phenotypes according to their initial pattern of muscle involvement: hyperCKemia when there are no clinical symptoms, LGMD2B when the proximal leg is first involved, MM when the distal part of leg is first involved, and proximodistal phenotype when there is proximal and distal weakness simultaneously at disease onset. Functional status was evaluated with a modified 0--9 grading system proposed by Gardner-Medwin and Walton (GM-W scale).\[[@ref24]\]

Mutation analysis {#sec2-2}
-----------------

Genomic DNA was extracted from peripheral blood cells or skeletal muscle specimens of the patients. In 41 patients, all 55 exons and the intron/exon boundary of the *DYSF* gene were amplified by PCR as previously described.\[[@ref25]\] The PCR products were directly sequenced using an ABI 3730XL automatic sequencing machine (Applied Biosystems, Life Technologies, Carlsbad, CA, USA). The sequences were read by Chromas software (<http://technelsium.com.au/wp/chromas>) and compared to the human *DYSF* sequence (NM_003494.3). In 48 patients, next generation sequencing (NGS) was applied with a neuromuscular disease panel (Agilent, Santa Clara, CA, USA) of 420 genes known to be associated with inherited muscular diseases. The exons and 10 bp of flanking splice sites were captured and subsequently sequenced on an Illumina HiSeq 2500 Sequencer (Illumina, San Diego, CA, USA). The reads were aligned by SOAPaligner for single-nucleotide polymorphism calling and other analyses. The sequencing files were mapped to reference sequences with Burrows-Wheeler Aligner and Picard tools, and then called with control samples with the GATK 3.0 HaplotypeCaller (Broad Institute, USA). Sanger sequencing with specific primers was conducted to confirm the mutations detected by NGS. In patients in whom only one mutation was detected, we further performed MLPA assay using a commercially available MLPA kit (SALSA MLPA probemix P268-A2 DYSF; MRC-Holland BV, Amsterdam, The Netherlands) which covered 40 of the 55 exons.

Interpretation of mutations found in this study {#sec2-3}
-----------------------------------------------

The mutations found in patients were determined to be disease-causing by the following criteria: (1) mutations reported in literature, in the HGMD database, Leiden Muscular Dystrophy pages database ([www.dmd.nl](www.dmd.nl)), or the UMD-DYSF mutations database ([www.umd.be/DYSF](www.umd.be/DYSF)); (2) novel null mutations, including nonsense mutations, frameshift mutations, canonical ±1 or 2 splice sites, and single exon or multiexon deletions; (3) novel missense mutations predicted to be disease-causing by a combination of four predictive software programs, including UMD-predictor (predicted as pathogenic/probably pathogenic),\[[@ref26]\] Mutation Taster (predicted as disease-causing),\[[@ref27]\] PolyPhen-2 (predicted as probably/possibly damaging),\[[@ref28]\] and SIFT software (J. Craig Venter Institute, USA) (predicted as deleterious); (4) novel intronic mutations predicted as disease-causing by MutationTaster (predicted as disease-causing)\[[@ref27]\] and Human Splicing Finder (<http://www.umd.be/HSF3>).\[[@ref29]\]

Statistical analysis {#sec2-4}
--------------------

All values were calculated using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). Values are presented as the mean ± standard error (SE) unless otherwise stated. Mann-Whitney *U*-test was used to test the significance of differences in the GM-W scale between different types of genetic mutations. Student\'s *t*-test was used to test the significance of differences in age of onset, disease duration, and serum creatine kinase (CK) level between the different types of genetic mutations. The difference in the clinical phenotypes between the two groups was analyzed by Chi-square test. A value of *P* ≤ 0.05 was considered statistically significant (two-tailed).

R[esults]{.smallcaps} {#sec1-3}
=====================

Geographic and clinical data {#sec2-5}
----------------------------

The patients in this study came from 27 provinces of mainland China, including 51 men and 38 women. A total of 87 patients were of Han ethnicity, one patient was of Hui ethnicity, and one patient was of Uygur ethnicity. Sixteen patients had a family history of muscle diseases. The mean age of onset was 21.1 ± 7.3 years (range 10--49 years). The mean disease duration was 7.4 ± 5.7 years (range 1 month to 25 years). Forty-five patients presented with LGMD2B, 31 with MM, 7 with PDM, and 6 were clinically asymptomatic and diagnosed with hyperCKemia. The median GM-W scale score was 4, ranging from 0 to 9. Eight patients were wheelchair-dependent. Serum CK ratio (defined as CK level/upper limit of normal range) varied widely, ranging from 10 to 187. Myopathic changes were found in 58 of the 63 patients who underwent examination by electromyography (EMG), and neurogenic changes were found in one patient. The remaining four patients showed normal EMG results. The detailed clinical data are provided in [Supplementary Table 1](#T1){ref-type="table"}.

###### 

Clinical information of patients in this study

  Patient number   Gender/age at diagnosis (years)   Age of onset (years)   Family history   Phenotype     GM-W scales at diagnosis   CK (×*N*)   Dysferlin ICH   Calf atrophy   EMG
  ---------------- --------------------------------- ---------------------- ---------------- ------------- -------------------------- ----------- --------------- -------------- ------------
  1                Female/34                         33                                      MM            2                          12          \-                             NA
  2                Female/30                         26                                      LGMD2B        3                          42          \-                             Normal
  3                Male/13                           13                                      HyperCKemia   0                          20          \-                             Myopathic
  4                Male/16                           14                                      LGMD2B        1                          118         \-                             Myopathic
  5                Female/28                         14                                      LGMD2B        4                          65          \-              \+             Myopathic
  6                Male/21                           15                     \+               MM            3                          106         \-              \+             NA
  7                Female/32                         12                     \+               LGMD2B        8                          157         \-              \+             NA
  8                Male/35                           20                                      LGMD2B        9                          NA          \-              \+             Myopathic
  9                Male/37                           18                                      MM            5                          29          \-              \+             Myopathic
  10               Female/49                         41                                      LGMD2B        7                          15          \-              \+             Myopathic
  11               Male/24                           18                                      MM            4                          52          \-              \+             Myopathic
  12               Female/28                         20                                      MM            4                          27          Reduced         \+             Myopathic
  13               Male/18                           15                                      HyperCKemia   1                          29          \-                             NA
  14               Male/16                           14                                      LGMD2B        4                          71          \-                             Myopathic
  15               Female/25                         24                                      LGMD2B        3                          64          \-                             Myopathic
  16               Female/18                         13                                      LGMD2B        4                          47          \-                             Myopathic
  17               Male/22                           16                                      MM            4                          59          \-              \+             Myopathic
  18               Female/36                         24                                      LGMD2B        7                          24          \-              \+             Myopathic
  19               Male/25                           22                                      LGMD2B        4                          40          \-                             Myopathic
  20               Male/28                           20                                      LGMD2B        4                          43          \-              \+             Myopathic
  21               Female/36                         29                                      PDM           4                          15          \-              \+             NA
  22               Female/33                         30                     \+               LGMD2B        4                          32          \-                             NA
  23               Female/28                         25                                      LGMD2B        5                          23          \-              \+             Myopathic
  24               Male/26                           25                                      PDM           4                          71          \-              \+             Myopathic
  25               Male/25                           16                     \+               MM            4                          34          \-              \+             Myopathic
  26               Male/25                           12                                      LGMD2B        5                          NA          Reduced         \+             NA
  27               Female/19                         17                                      MM            2                          80          \-              \+             Myopathic
  28               Male/15                           15                                      HyperCKemia   1                          187         Reduced                        NA
  29               Male/21                           14                                      MM            2                          71          \-              \+             Myopathic
  30               Male/35                           31                                      MM            4                          34          \-              \+             Myopathic
  31               Female/51                         49                                      LGMD2B        3                          11          \-              \+             Myopathic
  32               Female/49                         24                                      LGMD2B        7                          10          \-              \+             Myopathic
  33               Male/22                           22                                      PDM           1                          122         \-              \+             NA
  34               Male/26                           23                                      MM            8                          16          \-                             Myopathic
  35               Male/45                           31                     \+               LGMD2B        5                          NA          \-              \+             NA
  36               Male/36                           25                                      LGMD2B        5                          38          \-              \+             Myopathic
  37               Male/23                           21                     \+               PDM           2                          73          \-              \+             Myopathic
  38               Male/34                           29                                      MM            8                          20          \-              \+             Myopathic
  39               Female/35                         29                                      LGMD2B        5                          33          \-                             Myopathic
  40               Female/37                         28                                      LGMD2B        7                          17          Reduced         \+             Myopathic
  41               Male/22                           20                                      LGMD2B        2                          13          \-                             Myopathic
  42               Female/25                         14                     \+               MM            4                          57          \-              \+             Myopathic
  43               Female/32                         26                                      LGMD2B        2                          31          \-              \+             Myopathic
  44               Female/38                         28                                      MM            5                          21          \-              \+             Myopathic
  45               Male/24                           19                                      MM            4                          40          \-              \+             Myopathic
  46               Female/25                         22                                      MM            1                          21          \-              \+             Myopathic
  47               Male/24                           22                                      LGMD2B        3                          30          \-                             Myopathic
  48               Male/15                           15                                      LGMD2B        1                          31          \-                             NA
  49               Male/25                           18                                      MM            3                          51          Reduced         \+             Myopathic
  50               Male/17                           16                     \+               MM            1                          116         \-                             NA
  51               Male/16                           15                                      PDM           1                          120         \-              \+             Normal
  52               Male/16                           10                     \+               LGMD2B        2                          118         \-              \+             Myopathic
  53               Male/36                           14                                      MM            5                          29          \-              \+             Myopathic
  54               Male/42                           32                                      MM            NA                         24          --              \+             Myopathic
  55               Male/27                           16                                      MM            5                          37          --              \+             NA
  56               Male/26                           22                                      LGMD2B        2                          26          --              \+             Myopathic
  57               Female/25                         23                                      LGMD2B        NA                         22          --                             Myopathic
  58               Female/43                         15                                      LGMD2B        8                          10          --              \+             Myopathic
  59               Male/27                           16                                      MM            5                          76          --              \+             Myopathic
  60               Male/19                           19                                      HyperCKemia   0                          122         --                             Normal
  61               Male/33                           25                     \+               MM            2                          22          --              \+             NA
  62               Male/25                           16                                      MM            1                          38          --              \+             Myopathic
  63               Female/31                         18                                      LGMD2B        4                          NA          --              \+             NA
  64               Female/28                         14                     \+               PDM           5                          NA          --              \+             NA
  65               Male/41                           39                                      LGMD2B        5                          29          --              \+             Myopathic
  66               Male/24                           14                                      MM            2                          36          --              \+             Myopathic
  67               Female/26                         23                                      LGMD2B        5                          20          --              \+             Myopathic
  68               Male/36                           30                     \+               LGMD2B        4                          71          --              \+             Myopathic
  69               Male/26                           17                                      LGMD2B        8                          NA          NA              \+             NA
  70               Male/22                           14                                      LGMD2B        4                          55          NA              \+             NA
  71               Female/30                         28                                      LGMD2B        5                          NA          --                             Myopathic
  72               Male/29                           18                                      LGMD2B        5                          35          --              \+             NA
  73               Female/23                         18                                      PDM           5                          49          Reduced         \+             NA
  74               Female/32                         29                                      LGMD2B        4                          13          --                             Neurogenic
  75               Female/33                         26                                      MM            5                          16          --              \+             Myopathic
  76               Male/32                           26                                      MM            2                          43          --              \+             Myopathic
  77               Female/14                         14                                      LGMD2B        1                          93          --                             NA
  78               Female/28                         15                     \+               MM            4                          NA          --              \+             NA
  79               Male/13                           13                                      HyperCKemia   1                          47          --                             NA
  80               Male/45                           42                                      LGMD2B        2                          38          --                             Myopathic
  81               Male/30                           23                                      MM            4                          79          Reduced         \+             Myopathic
  82               Female/30                         19                                      LGMD2B        4                          24          --                             Myopathic
  83               Female/36                         26                                      LGMD2B        4                          17          Reduced         \+             NA
  84               Female/18                         16                     \+               HyperCKemia   0                          48          --                             Normal
  85               Female/23                         15                     \+               LGMD2B        8                          35          --              \+             Myopathic
  86               Female/37                         15                                      MM            8                          18          --              \+             Myopathic
  87               Female/26                         21                                      MM            4                          66          Reduced         \+             Myopathic
  88               Male/26                           15                     \+               LGMD2B        4                          44          --              \+             NA
  89               Male/31                           23                                      LGMD2B        NA                         31          --              \+             NA

NA: Not available; PDM: Proximodistal myopathy; MM: Miyoshi myopathy; LGMD2B: Limb girdle muscular dystrophy type 2B; GM-W: Gardner-Medwin and Walton; CK: Creatine kinase; ICH: Immunohistochemistry; EMG: Electromyography; + (Family history): patients with a family history of skeletal muscle diseases; -- (Dysferlin ICH): positive staining of dysferlin on muscle biopsy; + (Calf atrophy): patients with calf atrophy.

Analysis of mutations identified in this study {#sec2-6}
----------------------------------------------

Among the 89 index patients, 79 were demonstrated to carry two disease-causing (73 cases) or possibly disease-causing mutations (six cases), including 26 patients with homozygous mutations and 53 patients with compound heterozygous mutations. In the remaining 10 patients, only one heterozygous mutation was found. Notably, among 13 patients who were initially found to carry only one pathogenic mutation by Sanger sequencing or NGS, three were further identified to carry exonic deletions with MLPA \[[Figure 1](#F1){ref-type="fig"}\]. In these patients, we identified 105 different mutations, including 98 disease-causing and seven possibly disease-causing mutations \[[Supplementary Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}\]. Fifty-nine novel mutations were found, 52 of which were identified as disease-causing \[[Supplementary Table 2](#T2){ref-type="table"}\]. Seven novel missense mutations were determined as possibly disease-causing because of inconsistent results of different predicting softwares.

![Multiplex ligation-dependent probe amplification results of patients with exon deletions of dysferlin gene. Deletion of exon 48, exon 33, and exon 2 were identified in patient 22, 64, and 72, respectively (arrows).](CMJ-129-2287-g001){#F1}

###### 

Dysferlin gene mutations found in this study

  Patient number                                   Mutation name                   Protein change   Exon/intron   Domain         State               DNA sequencing   Mutation type
  ------------------------------------------------ ------------------------------- ---------------- ------------- -------------- ------------------- ---------------- -------------------
  1                                                c.863A\>T                       p.D288V          9             C2B            Homozygous          NGS              Missense
  2                                                c.1375dupA                      p.M459NfsX15     15            C2C            Heterozygous        NGS              Frameshift
  c.3036G\>C^†^                                    p.W1012C                        29               InnerDysF-C   Heterozygous   Missense                             
  3                                                c.2643+5G\>C^†^                 Abl.spl          25            InnerDysF-N    Heterozygous        NGS              Splice site
  c.3827T\>C^†^                                    p.L1276P                        34                             Heterozygous   Missense                             
  4                                                c.3059C\>T^†^                   p.P1020L         28            InnerDysF-C    Heterozygous        NGS              Missense
  c.3442+1G\>A^†^                                  Abl.spl                         IVS31                          Heterozygous   Splice site                          
  5                                                c.5302C\>T                      p.R1768W         47                           Homozygous          NGS              Missense
  6                                                c.1667T\>C                      p.L556P          19                           Heterozygous        Sanger           Missense
  c.3988C\>T                                       p.Q1330X                        37                             Heterozygous   Nonsense                             
  7                                                c.4894G\>T                      p.E1632X         45            C2F            Homozygous          NGS              Nonsense
  8                                                c.5414dupC^†^                   p.R1806Tfs\*22   48                           Homozygous          NGS              Frameshift
  9                                                c.1523-2A\>G^†^                 Abl.spl          IVS17                        Homozygous          NGS              Splice site
  10                                               c.3115C\>T^†^                   p.R1039W         29            InnerDysF-C    Heterozygous        NGS              Missense
  c.5245C\>T^†^                                    p.R1749C                        47                             Heterozygous   Missense                             
  c.5525G\>A                                       p.G1842D                        49               C2G           Heterozygous   Missense                             
  11                                               c.1375dupA                      p.M459Nfs\*15    15            C2C            Homozygous          NGS              Frameshift
  12                                               c.895G\>C                       p.G299R          9             C2B            Heterozygous        Sanger           Missense
  c.4756C\>T                                       p.R1586X                        43               C2F           Heterozygous   Nonsense                             
  13                                               c.1874A\>T^†^                   p.D625V          20                           Heterozygous        NGS              Missense
  c.2762C\>T^†^                                    p.S921L                         26               OuterDysF-N   Heterozygous   Missense                             
  c.3785delG^†^                                    p.G1263Afs\*82                  34                             Heterozygous   Frameshift                           
  14                                               c.1535_1553del^†^               p.F514Pfs\*107   18                           Heterozygous        Sanger           Frameshift
  c.4167+1G\>A                                     Abl.spl                         IVS38            C2E           Heterozygous   Splice site                          
  15                                               c.4988_4989delTC^†^             p.V1663Gfs\*47   45            C2F            Homozygous          NGS              Frameshift
  16                                               c.1523-2A\>G^†^                 Abl.spl          IVS17                        Heterozygous        NGS              Splice site
  c.2974T\>C                                       p.W992R                         28               InnerDysF-N   Heterozygous   Missense                             
  17                                               c.1180+5G\>A                    Abl.spl          IVS12         C2C            Heterozygous        NGS              Splice site
  c.4194delC                                       p.C1398fs                       39               C2E           Heterozygous   Frameshift                           
  18                                               c.3601C\>T                      p.Q1200X         33            C2D            Heterozygous        NGS              Nonsense
  c.4580T\>G^†^                                    p.L1527R                        42                             Heterozygous   Missense                             
  19                                               c.1930+2T\>G^†^                 Abl.spl          IVS20                        Homozygous          NGS              Splice site
  20                                               c.5884 C\>T                     p.Q1962X         52                           Homozygous          NGS              Nonsense
  21                                               c.3531_3533delCAT^†^            p\. 1178Idel     33            C2D            Homozygous          NGS              In frame deletion
  c.5355G\>A\*,^†^                                 p.M1785I                        48                             Homozygous                         Missense         
  22                                               Exon 48 deletion                                 40                           Heterozygous        NGS + MLPA       Exonic deletion
  c.4024C\>G                                       p.R1342G                        38               C2E           Heterozygous   Missense                             
  23                                               c.4022T\>C                      p.L1341P         38            C2E            Homozygous          NGS              Missense
  24                                               c.265C\>T                       p.R89X           4                            Heterozygous        NGS              Nonsense
  c.5509G\>A                                       p.D1837N                        49               C2G           Heterozygous   Missense                             
  25                                               c.1284+2T\>C                    Abl.spl          IVS13         C2C            Heterozygous        NGS              Splice site
  c.4756C\>T                                       p.R1586X                        43               C2F           Heterozygous   Nonsense                             
  26                                               c.144+1G\>A^†^                  Abl.spl          IVS2          C2A            Heterozygous        NGS              Splice site
  c.1393G\>C^†^                                    p.D465H                         15               C2C           Heterozygous   Missense                             
  27                                               c.3258_3259delAG^†^             p.D1087Cfs\*26   30            OuterDysF-C    Homozygous          NGS              Frameshift
  28                                               c.796_797delCT                  p.L266FfsX6      8             C2B            Heterozygous        NGS              Frameshift
  c.1377_1379del                                   p.R460del                       15               C2C           Heterozygous   In frame deletion                    
  29                                               c.4509+2_c.4509+ 6delTAAGG^†^   Abl.spl          IVS41                        Homozygous          Sanger           Splice site
  30                                               c.313dupC                       p.L105PfsX43     4                            Heterozygous        NGS              Frameshift
  c.5438T\>C^†^                                    p.L1813P                        49               C2G           Heterozygous   Missense                             
  31                                               c.1180+5G\>A                    Abl.spl          IVS12         C2C            Heterozygous        Sanger           Splice site
  c.3601C\>T                                       p.Q1201X                        33               C2D           Heterozygous   Nonsense                             
  32                                               c.863A\>T                       p.D288V          9             C2B            Heterozygous        NGS              Missense
  c.965T\>C                                        p.L322P                         11               FerI          Heterozygous   Missense                             
  33                                               c.2940delG                      p.L981FfsX76     28            InnerDysF-N    Heterozygous        NGS              Frameshift
  c.4200dupC                                       p.I1401HfsX8                    39               C2E           Heterozygous   Frameshift                           
  34                                               c.252delC^†^                    p.K85Rfs\*66     4             C2A            Homozygous          Sanger           Frameshift
  35                                               c.1992C\>A^†^                   p.Try664X        21                           Heterozygous        Sanger           Nonsense
  c.2997G\>T                                       p.W999C                         28               InnerDysF-N   Heterozygous   Missense                             
  36                                               c.799_800delTT                  p.F267LfsX5      8             C2B            Homozygous          Sanger           Frameshift
  37                                               c.937+1G\>A                     Abl.spl          IVS10                        Heterozygous        Sanger           Splice site
  c.3521-1G\>T^†^                                  Abl.spl                         IVS32            C2D           Heterozygous   Splice site                          
  38                                               c.2083delG^†^                   p.A695Pfs\*2     22            FerA           Homozygous          NGS              Frameshift
  39                                               c.176delT^†^                    p.L59Rfs\*92     3             C2A            Heterozygous        NGS              Frameshift
  c.5975delT^†^                                    p.V1992Efs\*20                  53                             Heterozygous   Frameshift                           
  40                                               c.4194delC                      p.C1398fs        39            C2E            Heterozygous        NGS              Frameshift
  c.4886+2T\>G^†^                                  Abl.spl                         IVS44            C2F           Heterozygous   Splice site                          
  41                                               c.610C\>T                       p.R204X          6                            Heterozygous        NGS              Nonsense
  c.3516_3517delTT                                 p.S1173X                        32               C2D           Heterozygous   Frameshift                           
  42                                               c.863A\>T                       p.D288V          9             C2B            Heterozygous        Sanger           Missense
  c.5077C\>T                                       p.R1693W                        46                             Heterozygous   Missense                             
  43                                               c.1667T\>C                      p.L556P          19                           Homozygous          NGS              Missense
  44                                               c.1180+5G\>A                    Abl.spl          IVS12         C2C            Homozygous          Sanger           Splice site
  45                                               c.3516_3517delTT                p.S1173X         32            C2D            Homozygous          Sanger           Frameshift
  46                                               c.5444G\>T                      p.C1815F         49            C2G            Homozygous          NGS              Missense
  47                                               c.799_800delTT                  p.F267LfsX5      8             C2B            Heterozygous        Sanger           Frameshift
  c.3181C\>T                                       p.Q1061RfsX59                   30                             Heterozygous   Nonsense                             
  48                                               c.1180+5G\>A                    Abl.spl          IVS12         C2C            Heterozygous        Sanger           Splice site
  c.4941_4942del CT^†^                             p.Y1648\*                       45               C2F           Heterozygous   Frameshift                           
  49                                               c.5302C\>T                      p.R1768W         47                           Homozygous          Sanger           Missense
  50                                               c.799_800delTT                  p.F267LfsX5      8             C2B            Homozygous          NGS              Frameshift
  c.863A\>T                                        p.D288V                         9                C2B           Heterozygous   Missense                             
  51                                               c.2997G\>A                      p.W999X          28            InnerDysF-N    Heterozygous        NGS              Nonsense
  c.4411_4433del                                   p.E1472Qfs\*21                  41                             Heterozygous   Frameshift                           
  52                                               c.863A\>T                       p.D288V          9             C2B            Heterozygous        Sanger           Missense
  c.1667T\>C                                       p.L556P                         19                             Heterozygous   Missense                             
  53                                               c.1254delC                      p.F419Lfs\*41    13            C2C            Heterozygous        NGS              Frameshift
  c.1956G\>A^†^                                    p.W652X                         21                             Heterozygous   Nonsense                             
  54                                               c.1375dupA                      p.M459NfsX15     15            C2C            Heterozygous        NGS              Frameshift
  c.3137G\>A                                       p.R1046H                        29               InnerDysF-C   Heterozygous   Missense                             
  55                                               c.1375dupA                      p.M459NfsX15     15            C2C            Heterozygous        Sanger           Frameshift
  c.1464delT                                       p.G489EfsX4                     16                             Heterozygous   Frameshift                           
  56                                               c.3137G\>A                      p.R1046H         29            InnerDysF-C    Homozygous          Sanger           Missense
  57                                               c.144+1G\>A^†^                  Abl.spl          IVS2          C2A            Heterozygous        Sanger           Splice site
  c.1375dupA                                       p.M459NfsX15                    15               C2C           Heterozygous   Frameshift                           
  58                                               c.3988C\>T                      p.Q1330X         37                           Heterozygous        Sanger           Nonsense
  c.1180+5G\>A                                     Abl.spl                         IVS12            C2C           Heterozygous   Splice site                          
  59                                               c.1284+1G\>A^†^                 Abl.spl          IVS13         C2C            Homozygous          Sanger           Splice site
  60                                               c.937+1G\>A                     Abl.spl          IVS10                        Heterozygous        Sanger           Splice site
  c.4756C\>T                                       p.R1586X                        43               C2F           Heterozygous   Nonsense                             
  61                                               c.680T\>C^†^                    p.I227T          7             C2B            Heterozygous        Sanger           Missense
  c.3988C\>T                                       p.Q1330X                        37                             Heterozygous   Nonsense                             
  62                                               c.755C\>T                       p.T252M          7             C2B            Heterozygous        Sanger           Missense
  c.3789_3796del^†^                                p.S1264Vfs\*9                   34                             Heterozygous   Frameshift                           
  63                                               c.1708C\>T^†^                   p.Q570X          19                           Heterozygous        Sanger           Nonsense
  c.4011delG^†^                                    p.A1338Hfs\*7                   38               C2E           Heterozygous   Frameshift                           
  64                                               c.339delA^†^                    p.A115Pfs\*36    4                            Heterozygous        Sanger + MLPA    Frameshift
  Exon 33 deletion                                                                 33               C2D           Heterozygous   Exonic deletion                      
  65                                               c.1180+4delC^†^                 Abl.spl          IVS12         C2C            Heterozygous        Sanger           Splice site
  c.1708C\>T^†^                                    p.Q570X                         19                             Heterozygous   Nonsense                             
  66                                               c.1906C\>T^†^                   p.Q636X          20                           Heterozygous        NGS              Nonsense
  c.2810+5G\>A^†^                                  Abl.spl                         IVS20                          Heterozygous   Splice site                          
  67                                               c.610C\>T                       p.R204X          6                            Heterozygous        Sanger           Nonsense
  c.1134_1166del                                   p\. 359A_368Adel                12               C2C           Heterozygous   In frame deletion                    
  68                                               c.4989_4990insCGGT^†^           p.V1664Rfs\*48   45                           Homozygous          Sanger           Frameshift
  69                                               c.265C\>T                       p.R89X           4                            Heterozygous        NGS              Nonsense
  c.6080G\>A^†^                                    p.W2027X                        54                             Heterozygous   Nonsense                             
  70                                               c.792+1G\>A^†^                  Abl.spl          IVS7          C2B            Heterozygous        NGS              Splice site
  c 965T\>C                                        p.L322P                         11               FerI          Heterozygous   Missense                             
  71                                               c.5740G\>A^†^                   p.D1914N         51            C2G            Heterozygous        Sanger + MLPA    Missense
  72                                               c.567delA^†^                    p.P190Lfs\*37    6                            Heterozygous        NGS + MLPA       Frameshift
  Exon 2 deletion                                                                  3                C2A           Heterozygous   Exonic deletion                      
  73                                               c.1165G\>A                      p.E389K          12            C2C            Heterozygous        Sanger           Missense
  c.2997G\>T                                       p.W999C                         28               InnerDysF-N   Heterozygous                       Missense         
                                                                                                                                                                      
  **Patients with one disease-causing mutation**                                                                                                                      
                                                                                                                                                                      
  74                                               c.2997G\>T                      p.W999C          28            InnerDysF-N    Heterozygous        NGS              Missense
  c.5639C\>G\*,^†^                                 p.A1880G                        50               C2G           Heterozygous   Missense                             
  75                                               c.3702T\>G^†^                   p.Y1234X         33            C2D            Heterozygous        NGS              Nonsense
  c.5511C\>A\*,^†^                                 p.D1837E                        49               C2G           Heterozygous   Missense                             
  c.5516A\>T\*,^†^                                 p.Y1839F                        49               C2G           Heterozygous   Missense                             
  76                                               c.3032-3C\>G^†^                 Abl.spl          IVS28         InnerDysF-N    Heterozygous        NGS              Splice site
  c.5639C\>G^†^                                    p.A1880G                        50               C2G           Heterozygous   Missense                             
  77                                               c.1375dupA                      p.M459NfsX15     15            C2C            Heterozygous        NGS              Frameshift
  c.5197A\>G\*,^†^                                 p.I1733V                        46                             Heterozygous   Missense                             
  78                                               c.4497delT                      p.F1499LfsX4     41                           Heterozygous        Sanger           Frameshift
  c.5216C\>A\*,^†^                                 p.P1739Q                        41                             Heterozygous   Missense                             
  79                                               c.5792G\>C\*,^†^                p.R1931P         52                           Heterozygous        NGS              Missense
  c.5511C\>A\*,^†^                                 p.D1837E                        49               C2G           Heterozygous   Missense                             
  c.5516A\>T\*,^†^                                 p.Y1839F                        49               C2G           Heterozygous   Missense                             
  80                                               c.3112C\>T                      p.R1038X         29            InnerDysF-C    Heterozygous        NGS + MLPA       Nonsense
  81                                               c.4513T\>A^†^                   p.Y1505N         42                           Heterozygous        Sanger + MLPA    Missense
  82                                               c.1464delT                      p.G489EfsX4      16                           Heterozygous        Sanger + MLPA    Frameshift
  83                                               c.610C\>T                       p.R204X          6                            Heterozygous        Sanger + MLPA    Nonsense
  84                                               c.567delA^†^                    p.P190Lfs\*37    6                            Heterozygous        Sanger + MLPA    Frameshift
  85                                               c.1464delT                      p.G489EfsX4      16                           Heterozygous        Sanger + MLPA    Frameshift
  86                                               c.3725G\>A                      p.R1241H         34            C2D            Heterozygous        Sanger + MLPA    Missense
  87                                               c.610C\>T                       p.R204X          6                            Heterozygous        Sanger + MLPA    Nonsense
  88                                               c.5803C\>A^†^                   p.P1935T         52                           Heterozygous        Sanger + MLPA    Missense
  89                                               c.4063_4064insT                 p.P1355SfsX27    38            C2E            Heterozygous        Sanger + MLPA    Frameshift

\*Mutations with undetermined pathogenicity; ^†^Novel mutations. NGS: Next generation sequencing; Sanger: Sanger sequencing; MLPA: Multiplex ligation-dependent probe amplification.

![Positioning of dysferlin gene mutations identified in this study along the dysferlin protein sequence. Different domains are indicated by rectangles. Vertical lines above the protein indicate homozygous mutations while the vertical lines below the protein denote the heterozygous mutations.](CMJ-129-2287-g002){#F2}

The allele frequencies of disease-causing mutations found in this study were as follows \[[Table 1](#T3){ref-type="table"}\]: missense mutations (30.06%), nonsense mutations (17.18%), frameshift mutations (30.67%), in-frame deletions (2.45%), intronic mutations (17.79%), and exonic rearrangement (1.84%). These mutations span the whole length of the *DYSF* gene. However, the C2B and C2C domain demonstrated the highest frequency of mutations in this study \[[Table 2](#T4){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}\].

###### 

Classification of disease-causing mutations of dysferlin gene in this study

  Mutation types         Mutations, *n*   Allele frequency (%)
  ---------------------- ---------------- ----------------------
  Point mutations        77               47.24
   Missense              49               30.06
   Nonsense              28               17.18
  Deletion/insertion     54               33.13
   Frameshift            50               30.67
   In-frame              4                2.45
  Intronic mutation      29               17.79
  Exonic rearrangement   3                1.84
                                          
  Total                  163              100.00

###### 

Distribution of dysferlin gene mutations in this study

  Domains                         Proportion of mutations in this domain (%)
  ------------------------------- --------------------------------------------
  C2 domain A                     3.70
  C2 domain B                     9.88
  Ferlin family domain FerI       1.23
  C2 Domain C                     13.58
  Ferlin family domain FerA       1.23
  Ferlin family domain FerB       0.00
  Outer DysF domain, N.terminal   0.62
  Inner DysF domain, N.terminal   4.94
  Inner DysF domain, C.terminal   4.32
  Outer DysF domain, C.terminal   1.23
  C2 domain D                     6.17
  C2 domain E                     5.56
  C2 domain F                     5.56
  C2 domain G                     3.70
  Transmembrane domain            0.00
                                  
  Total                           61.72

Ten recurrent mutations, which were found in more than three unrelated patients, are listed in [Table 3](#T5){ref-type="table"}. Four of these mutations (c.863A\>T, c.1375dupA, c.1667T\>C, and c.3988C\>T) have only been reported in the Chinese population.

###### 

Recurrent mutations of dysferlin gene identified in this study

  Mutations        Protein changes   Domains       Patient number
  ---------------- ----------------- ------------- -----------------------
  c.610C\>T        p.R204X                         41, 67, 83, 87
  c.799_800delTT   p.F267LfsX5       C2B           36, 47, 50
  c.863A\>T        p.D288V           C2B           1, 32, 42, 50, 52
  c.1180+5G\>A     Abl.spl           C2C           17, 31, 44, 48, 58
  c.1375dupA       p.M459NfsX15      C2C           2, 11, 54, 55, 57, 77
  c.1464delT       p.G489EfsX4                     55,82,85
  c.1667T\>C       p.L556P                         6, 43, 52
  c.2997G\>T       p.W999C           InnerDysF-N   35, 73, 74
  c.3988C\>T       p.Q1330X                        6, 58, 61
  c.4756C\>T       p.R1586X          C2F           12, 25, 60

Genotype-phenotype correlation {#sec2-7}
------------------------------

We divided the patients in this study into two groups: (1) patients with at least one missense mutation or in- frame deletion/insertion and (2) patients with no missense mutation or in- frame deletion/insertion. No statistically significant difference was detected between these two groups regarding age of onset, disease duration, phenotype, GM-W scale, and serum CK level (*P* \>0.05).

D[iscussion]{.smallcaps} {#sec1-4}
========================

The patients enrolled in this study came from 27 of the 34 provinces of China, which enabled us to better characterize the genetic spectrum of patients with dysferlinopathy in mainland China.

As previously reported, the mutations found in this study span the whole length of the *DYSF* gene, and no mutational hot spots were identified. However, we found that *DYSF* mutations in Chinese patients clustered in the N-terminal region of the gene, especially in and around the C2C and C2B domains. In contrast, previously reported *DYSF* mutations were distributed evenly along the *DYSF* gene.\[[@ref18]\] N-terminal clustering was only observed in a group of South Korean patients with dysferlinopathy.\[[@ref5]\] Interestingly, four of the ten recurrent mutations found in this study (c.799_800delTT, c.863A\>T, c.1180+5G\>A, and c.1375dupA) were located in the C2B and C2C domains. The N-terminal clustering of *DYSF* mutations in Chinese patients was partly attributable to these recurrent mutations. All patients with the c.1375dupA mutation originated from northern China, indicating a potential founder effect of this mutation.

The dysferlin protein consists of seven C2 domains (C2A--C2G) \[[Figure 2](#F2){ref-type="fig"}\],\[[@ref30]\] which are highly conserved and functions in calcium-dependent phospholipid binding. The affinity of calcium- and phospholipid-binding for each domain varies greatly. For example, the C2B domain was predicted to have no calcium-binding capacity.\[[@ref30]\] In line with this hypothesis, quantitative study revealed that the C2B domain is one of the domains with lowest affinity for calcium-dependent membrane binding.\[[@ref31]\] In addition, by constructing mini-dysferlin molecules, Azakir *et al*.\[[@ref32]\] found that the deletions of the dysferlin C2B domains have no impact on the sarcolemmal localization of dysferlin and the membrane repair of injured muscle cell. However, in this study, the C2B domain was the second most frequently affected domain, which was partly attributed to the recurrent mutation c.863A\>T found in Chinese patients. To date, a very few missense mutations affecting the calcium-binding residues have been identified. c.863A\>T results in a substitution of aspartate 288 by valine, which was predicted to be a key calcium-binding residue in this domain.\[[@ref30]\] The recurrence of the missense mutation c.863A\>T implied the importance of the C2B domain for the function of dysferlin.

The proportion of different types of mutations in Chinese patients with dysferlinopathy varied among previous studies.\[[@ref4][@ref21][@ref23]\] We found that there were fewer missense mutations in the current study than previously reported,\[[@ref18]\] which might be due in part to the exclusion of the possibly disease-causing missense mutations in this study. Interestingly, the missense mutations identified in this study were located mainly in the C2B domain and inner *DysF* domain. The c.863A\>T was found in five of eight patients carrying missense mutations in the C2B domain. Of all nine patients carrying missense mutations in the Inner *DysF* domain, eight patients were carrying mutations disrupting the arginine/tryptophan (R/W) stacks.\[[@ref33]\]

In this study, we first determined the existence of exonic rearrangements in Chinese patients. Only a few reports have described exonic rearrangements in patients with dysferlinopathy.\[[@ref10][@ref19][@ref34]\] Genomic deletions/duplications were found in five of 12 patients with one pathogenic mutation using the MLPA method.\[[@ref10]\] In this study, the frequency of exonic rearrangements was three in 13 patients with one pathogenic mutation. At present, there is no information available on the percentage of defects in the *DYSF* gene caused by deletions/duplications of complete exons. In our cohort, the allele frequency was estimated to be 3/178. However, we did not perform the MLPA test in patients with compound heterozygous or homozygous mutations. In addition, the MLPA kit we used only covers 40 of the 55 exons in the *DYSF* gene, so the frequency might be higher than expected. Given the high frequency of exonic rearrangements in patients with one disease-causing mutation, further MLPA analysis in these patients is recommended. In addition, in patient 22, we first identified a single exonic deletion by NGS using a copy number variation (CNV) calling algorithm, which incorporates read-depth statistics, allele zygosity analysis, and breakpoints detection. CNV calls were further confirmed by MLPA assays, providing a conclusive molecular diagnosis that would not be possible by routine Sanger sequencing alone.

In this study, we identified 59 novel mutations, 52 of which were determined to be disease-causing. However, confirmation of the seven novel missense mutations was impossible using a bioinformatic approach because of conflicting results among different software programs. The clinical diagnoses of dysferlinopathy in patients (Six patients in total: P21, 74, 75, 77, 78 and 79, [Supplementary Table 1](#T1){ref-type="table"} and [Supplementary Table 2](#T2){ref-type="table"}) carrying these mutations were confirmed based on the typical history and pathological study (especially the immunohistochemistry staining of dysferlin). In five of these patients (P21, 74, 75, 77, and 79), mutations of other muscular dystrophies related genes were ruled out by NGS panel based on 420 different genes, and exonic rearrangements were ruled out by the CNV calling algorithm \[[Supplementary Table 2](#T2){ref-type="table"}\]. Therefore, the pathogenicity of these mutations could not be ruled out. Patient 78 had a family history of dysferlinopathy, and negative dysferlin expression was confirmed in her and her affected brother. As the mutation c.5216C\>A was also identified in the siblings by Sanger sequencing, it is quite possible that c.5216C\>A was disease-causing. Further study at the mRNA level is needed to achieve definitive genetic diagnoses in these patients.

The novel mutations identified in this study, accounting for about 10% of all mutations reported to date, greatly expand the genetic spectrum of dysferlinopathy.

In conclusion, *DYSF* mutations in Chinese patients clustered in the N-terminal region of the *DYSF* gene. Exonic rearrangements were found in 23% of patients with only one pathogenic mutation identified by Sanger sequencing or NGS. Novel mutations found in this study greatly expand the mutational spectrum of dysferlinopathy.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.

Financial support and sponsorship {#sec2-8}
---------------------------------

Nil.

Conflicts of interest {#sec2-9}
---------------------

There are no conflicts of interest.

**Edited by:** Yi Cui
